By mining the RNA-sequencing data of the Breast Cancer Cohort of TCGA (The Cancer Genome Atlas: https://cancergenome.nih-gov/) and microarray data of METABRIC, we evaluated the Kaplan-Meier survival rates of patients grouped according to high expression levels of IGF-1 or IGF-1R (or both) (mRNA Z-score more than 0) and low expression levels of IGF-1 and IGF-1R (mRNA Z-score equal or less than 0). This evidence concerns the gene IGF1R and breast carcinoma.